IDH1 and glioblastoma: Recently published work from our laboratory showed that PARP and ATR inhibitors synergize in the common glioblastoma mutation in isocitrate dehydrogenase 1/2 (IDH1/2), so perhaps MMR-deficiencies may also benefit from this combination43.